GAST and neoplasm: Next, we examined the safety and efficacy of the CCK-BR targeted NP to deliver mutant KRASG12D siRNA alone, gastrin (GAST) siRNA alone, or both siRNAs in combination in mice bearing orthotopic human pancreatic tumors with a heavy tumor burden to represent the advanced stage in which most human subjects present at diagnosis.